Trial Profile

Phase 1 First in Human Dose Escalation and Safety Study of Topical ENS-002 for Atopic Dermatitis in Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENS 002 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; First in man
Acronyms EnSync
Sponsors Concerto Biosciences

Most Recent Events

12 Dec 2024 Planned End Date changed from 20 Dec 2024 to 20 May 2025.
12 Dec 2024 Planned primary completion date changed from 20 Dec 2024 to 20 May 2025.
19 Nov 2024 According to the Concerto Biosciences media release, company announced the first participant has been dosed in their Phase 1, first-in-human trial of ENS-002.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com